Luke Nordquist, MD, FACP, a urologic medical oncologist and CEO of the Urology Cancer Center and GU Research Network, discusses a multicenter, prospective study of radium-223 retreatment in metastatic castration-resistant prostate cancer (mCRPC).
Luke Nordquist, MD, FACP
Advertisement
Articles by Luke Nordquist, MD, FACP
Advertisement
Latest Updated Articles
Dr. Luke Nordquist on Radium-223 RetreatmentAugust 3rd 2016
Advertisement
Advertisement
Trending on OncLive
1
FDA Finalizes 3 Guidance Documents to Broaden Cancer Clinical Trial Eligibility Criteria
2
Dr Le on Choosing Between Zongertinib and Sevabertinib in HER2 TKD–Mutant NSCLC
3
Innovative Screening Approaches, Targeted Therapies, and Team-Based Care Drive Head and Neck Oncology Advances
4
AI Tools Show Early Promise Across Drug Discovery, Clinical Decision-Making in Lung Cancer
5